CytoDyn CEO Dr. Nadir Pourhassan and CMO Dr. Scott Kelly to Hold Conference Call (Thursday 4 pm EDT) to Provide Updates on CytoDyn’s COVID-19 Phase 2 and 3 Trials, NASH, BLA for HIV, and Manufacturing of Leronlimab in 2020-2021

On June 9, 2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Nader Pourhassan, PhD, President and Chief Executive Officer, and Scott Kelly, MD, Chairman, Chief Medical Officer, and Head of Business Development, will host an investment community conference call on Thursday, June 11, 2020, to provide a comprehensive update on several recent clinical and regulatory developments, potential uplisting and its timing, potential licensing, and/or distribution agreements. Management will dedicate approximately 30-40 minutes to address questions from analysts and investors. The conference call will take place on Thursday, June 11, 2020, beginning at 1:00 p.m. PDT / 4:00 p.m. EDT. Dial-In access is available at 877-407-2986 US / 201-378-4916 International. A live audio webcast may also be accessed via CytoDyn’s corporate website at under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, and to download and install any necessary software. The webcast can also be accessed via the following link: A replay of the conference call will be available until July 11, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13705221.
Login Or Register To Read Full Story